Fibrocell Science Inc

Fibrocell Science — Investor Presentation (May 2018)

21 slides from Fibrocell Science's investor presentation, May 10, 2018

  1. Slide 1: Corporate Presentation May 10, 2018

    Corporate Presentation May 10, 2018

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward- looking statements for this p

  3. Slide 3: Investment Highlights

    Investment Highlights • Medical breakthroughs for rare diseases of the skin and connective tissue Focus on Rare Skin • Unmet needs with no approved therapies Diseases • Significant mortality and morbidity impact on pediatric populations Proprietary Ex-Vivo Gene • Autologous fibroblasts derived from

  4. Slide 4: Development Pipeline

    Development Pipeline Phase 1/2 Program Condition Target Research Pre-Clinical Clinical Trials FDA Designations Orphan Drug Type VII FCX-007 Recessive Dystrophic Rare Pediatric Disease Epidermolysis Bullosa Collagen (RDEB) Fast Track FCX-013 Moderate to Severe Orphan Drug MMP-1 Localized Scleroderma

  5. Slide 5: Our Proprietary Fibroblast Platform

    Our Proprietary Fibroblast Platform Viral Vector Delivery Vehicle Vector Autologous fibroblasts Lentiviral vector gene transfer • Readily sourced, as fibroblasts • 3rd generation and self- are the most common cell type in skin and connective tissue inactivating • • Reduced rejection and Accommodates

  6. Slide 6: Personalized Biologics Approach

    Personalized Biologics Approach 6

  7. Slide 7: FCX-007 – Recessive Dystrophic Epidermolysis Bullosa

    FCX-007 – Recessive Dystrophic Epidermolysis Bullosa FCX-007 is a dermal fibroblast transduced with a lentiviral vector encoded with the gene for type VII collagen Orphan Drug Designation Rare Pediatric Disease Designation Fast Track Designation 7

  8. Slide 8: About RDEB

    About RDEB Recessive Dystrophic Epidermolysis Bullosa (RDEB) is a monogenic disease resulting in chronic skin blistering and wounding Disease Current Treatments Epidemiology • Cause: A mutation in the • Current treatments only Dystrophic EB (DEB) COL7A1 gene that address symptoms ~5,500 – 12,500 US3

  9. Slide 9: FCX-007 Phase 1/2 Clinical Trial Design

    FCX-007 Phase 1/2 Clinical Trial Design A Phase 1/2 Trial of FCX-007 (Genetically-Modified Autologous Human Dermal Title Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa (RDEB) NCT02810951 Primary Objective To evaluate the safety of a single intradermal injection session of FCX-007 Second

  10. Slide 10: FCX-007 Interim Data Readout

    FCX-007 Interim Data Readout • Interim readout of data for three NC1+ adult Phase 1 patients, 12 weeks post- administration • Single injection session of FCX-007 to target wounds or preliminary safety assessment • Five wounds treated over three patients ranging from 4.4cm2 to 13.1cm2 in size • FCX-0

  11. Slide 11: FCX-007 Interim Readout: Wound Healing

    FCX-007 Interim Readout: Wound Healing • Digital images captured and tracings performed Post- Treated or Percent Healing Number of . Skin tattoos and transparent overlays used as landmarks Baseline Untreated Wounds Meeting Visit Wounds Criteria • Wounds monitored in the study prior to dosing were op

  12. Slide 12: FCX-007 Interim Readout: Pharmacology

    FCX-007 Interim Readout: Pharmacology • Variable pharmacology signals detected throughout the data set in each patient for one or more assays through 12 weeks post-administration (qPCR, electron microscopy, immunofluorescence) . Anchoring fibrils have not been detected to date, whereas COL7 mRNA and

  13. Slide 13: FCX-013 – Moderate to Severe Localized Scleroderma

    FCX-013 – Moderate to Severe Localized Scleroderma FCX-007 is a dermal fibroblast transduced with a lentiviral vector encoded with the gene for MMP-1, under control of the RheoSwitch Therapeutic System® (RTS®) Orphan Drug Designation Rare Pediatric Disease Designation 13

  14. Slide 14: About Localized Scleroderma

    About Localized Scleroderma Disease Epidemiology • Excess production of collagen • Localized Scleroderma characterized by skin fibrosis ~160,000 sufferers US5 comprised of different sub- • Focus on moderate to severe types subtypes . ~90,000 patients are • Thickening may extend to considered moderat

  15. Slide 15: FCX-013 Moving into Clinical Trials

    FCX-013 Moving into Clinical Trials • Product profile . Dermal fibroblasts genetically modified using lentivirus and encoded for matrix metalloproteinase 1 (MMP-1), a protein responsible for breaking down collagen . Incorporates Intrexon’s RheoSwitch Therapeutic System® (RTS®) to control protein exp

  16. Slide 16: FCX-013 Phase 1/2 Clinical Trial Design

    FCX-013 Phase 1/2 Clinical Trial Design A Phase 1/2 Study of a Combination of FCX-013 (Genetically-Modified Human Title Dermal Fibroblasts) plus Veledimex for the Treatment of Moderate to Severe Scleroderma (Morphea) Primary Objective To evaluate the safety of a single intradermal injection session

  17. Slide 17: FCX-013 Proof-of-Concept Study

    FCX-013 Proof-of-Concept Study • Study Design D0 D28 D29 D39 . Bleomycin treated SCID mouse model . N=30 mice over test and control groups Blecomycin treatments Ligand Treatment . Assessed histologically for reduction of dermal thickness and sub-dermal muscle in the presence Cell Harvest skin of FCX

  18. Slide 18: Manufacturing Experience and Solutions

    Manufacturing Experience and Solutions Fibrocell’s existing cGMP cell therapy manufacturing facility in Exton, PA has been designated as the production site for FCX-007 and FCX-013 • ~13,000 square foot facility includes: . Cleanroom for cell culture manufacturing . On-site quality control testing l

  19. Slide 19: FCX-007 Anticipated Milestones 2018-2019

    FCX-007 Anticipated Milestones 2018-2019 January 2018 2Q2018 3Q2018 1Q2019 FDA allowance of Interim Phase 1 data Complete enrollment Interim data readout pediatric patient readout and trial of Phase 2 patients and trial update FCX-007 enrollment in Phase 2 update Dose first Phase 2 patient FCX-013 M

  20. Slide 20: Investment Highlights

    Investment Highlights • Medical breakthroughs for rare diseases of the skin and connective tissue Focus on Rare Skin • Unmet needs with no approved therapies Diseases • Significant mortality and morbidity impact on pediatric populations Proprietary Ex-Vivo Gene • Autologous fibroblasts derived from

  21. Slide 21: References

    References 1 Fine, J. et. al. (ed.). Epidermolysis Bullosa: Clinical, Epidemiologic, and Laboratory Advances and the Findings of the National Epidermolysis Bullosa Registry. The John Hopkins University Press, Baltimore, MD, 1999. 2 The Dystrophic Epidermolysis Research Association of America (DebRA)

Fibrocell Science — Investor Presentation (May 2018) on 6ix